Janssen to fund Genmab renaissance with daratumumab licensing deal
This article was originally published in Scrip
Janssen Biotech (J&J) has agreed a global licence and development deal for Genmab's daratumumab (HuMax(r)-CD38), a human CD38 monoclonal antibody, which is in clinical testing for multiple myeloma. Genmab will receive $55 million up front under the agreement, and J&J will invest DKK475 million (around $80 million) in Genmab, making it the Danish biotech company's largest shareholder.
You may also be interested in...
Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone in multiple myeloma, is more effective than current standards of care in certain front-line settings.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.